DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration

Rockville, MD  20857

NDA 21-153/S-023

AstraZeneca LLP
Attention: George A. Kummeth
Director Regulatory Affairs
1800 Concord Pike, P.O. Box 8355
Wilmington, Delaware  19803-8355

Dear Mr. Kummeth:

Please refer to your new drug application (NDA) dated December 15, 2005, received
December 15, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for
Nexium® (esomeprazole magnesium) Delayed-Release Capsules.

We acknowledge receipt of your submissions dated December 15, 2005 (two amendments); and
April 13, 2006; April 17, 2006; August 24, 2006; and September 6, 2006.

This supplemental new drug application provides for the use of NEXIUM®
(esomeprazole magnesium) Delayed-Release Capsules for the treatment of pathological hypersecretory
conditions including Zollinger-Ellison Syndrome.

We completed our review of this application, as amended. This application is approved, effective on
the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling and/or submitted labeling of
September 27, 2006.

All applications for new active ingredients, new dosage forms, new indications, new routes of
administration, and new dosing regimens are required to contain an assessment of the safety and
effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are
waiving the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional materials that you propose to use for
this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to
this division and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266
If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Marlène G. Swider, Regulatory Project Manager, at (301) 796-2104.

Sincerely,

Joyce A. Korvick, M.D., M.P.H.
Deputy Director and Acting Director
Division of Gastroenterology Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Joyce Korvick
10/11/2006 04:18:39 PM